Xencor, Inc. (XNCR) SEC Filings & Earnings Calls

XmAb541 dose-limiting hearing impairment may limit therapeutic window.

“Reversible hearing impairment limited XmAb541 drug exposure due to dose interruptions and reductions; potentially on target for CLDN6.” · word for word

CLDN6 remains a challenging tumor target; combination strategy may not overcome toxicity.

“CLDN6 remains a challenging tumor target; combination with XmAb808 may expand therapeutic window but uncertain.”

Royalty dispute with Alexion resolved but future royalty stream uncertain

“On March 4, 2026, Alexion informed the Company that it had taken the position that it did not owe additional royalties for U.S. sales of Ultomiris and did not intend to make future payments for sales in the U.S. under the parties' agreement.” · word for word

Patent litigation with Merus resolved

“On August 5, 2024, Merus N.V. filed a complaint in the District of Delaware alleging that the Company's manufacture, use, offer for sale, sale and/or importation of common light chain antibodies and heterodimeric antibodies infringe certain claims of Merus patents.”

Significant cash burn and net loss

“Net loss attributable to Xencor, Inc. $ (150,645) for six months ended June 30, 2026 vs $ (79,243) for six months ended June 30, 2025.”

Royalty dispute resolved, but future U.S. royalty stream eliminated; reliance on ex-U.S. royalties and pipeline success remains.

“Alexion will have no further obligation to pay royalties on U.S. sales of Ultomiris.” · word for word

Revenue decline of 86% due to milestone comparison, indicating lumpy revenue stream typical of clinical-stage biotech

“Revenue for Q1 2026 was $4.5 million, compared to $32.7 million for same period in 2025”

R&D expenses increasing 10% year-over-year, indicating continued investment in pipeline

“R&D expenses $64.7M vs $58.6M in prior year”

Royalty revenue dispute

“Alexion notified the Company that it does not owe additional U.S. royalties for Ultomiris, leading to a $6.6 million reduction in royalty revenue.” · word for word

Cash burn

“Cash and cash equivalents declined 74% from year-end 2025 to $14.2 million, with net cash used in operations of $67.6 million in Q1 2026.”

Marketable equity securities volatility

“Unrealized losses on marketable equity securities were $51.9 million in Q1 2026, primarily due to the decline in Zenas BioPharma's stock price.”

Patent litigation

“Merus N.V. filed a patent infringement lawsuit against the Company; the Company has filed for inter partes review.”

Early-stage data; regulatory and competitive risks remain.

“forward-looking statements caution about development risks”

Material weaknesses in internal control over financial reporting

“the Company identified the following material weaknesses in the Company’s internal control over financial reporting to have existed as of December 31, 2024 and 2023: (i) a deficiency in the design of controls related to the Company’s review of the accounting treatment of the proceeds from the sale of future royalties as part of our non-routine transactions, ” · word for word

Restatement of prior financial statements

“the Company’s (i) audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 ... and (ii) unaudited financial statements included in each of the Company’s Quarterly Reports on Form 10-Q for the quarterly periods ending September 30, 2024, June 30, 2024, and March 31, 2024 ... should no longer be rel” · word for word

Reliance on future equity grants for talent retention

“Our future success depends on our ability to attract, retain and motivate highly qualified employees across our entire organization, and competition for talent in oncology and autoimmune drug development remains exceptionally strong.” · word for word

Clinical-stage pipeline risk

“Xencor is a clinical development-stage biotechnology company advancing cutting-edge XmAb® engineered antibodies for patients affected by cancer and autoimmune disease.” · word for word

Loss of collaboration revenue and pipeline asset.

“Sole active collaboration product under Agreement terminated; Roche removed from pipeline.”

Loss of expected royalty revenue from Ultomiris US sales; potential legal dispute.

“Licensee informed the Company that it does not owe any additional royalties for sales of Ultomiris in the United States”

Clinical-stage biotech with no approved products; revenue dependent on collaboration and royalty income

“Clinical-stage biopharmaceutical company; revenue declined 46.6% YoY in Q4; cash burn expected in FY2026”

Pipeline execution risk; multiple programs in early stages

“XmAb819, XmAb541, XmAb942 all in Phase 1 or 2; pivotal studies not yet initiated”

Tariff and Trade War Risk

“A trade war or other governmental action related to tariffs or international trade agreements or policies has the potential to disrupt our research activities, increase the cost of materials purchased to develop our products, and/or affect the United States or global economy or certain sectors thereof.” · word for word

Data Privacy Compliance Risk

“Given the breadth and depth of changes in data protection obligations, preparing for and complying with these requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, CROs, contractors or consultants that proces” · word for word

Cybersecurity Risk

“Any system failure, accident or security breach that causes interruptions in our own, in collaborators’ or in third-party service vendors’ operations could result in a material disruption of our drug discovery and development programs.” · word for word

Clinical-stage company with no approved products; reliance on pipeline success and partnerships.

“Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered antibodies.”

Government shutdown delays FDA reviews

“Recently, beginning on October 1, 2025, the U.S. government shut down and remains shut down as of the date of this filing, during which time certain regulatory agencies, such as the FDA and the SEC, have furloughed critical employees and stopped critical activities.” · word for word

IRA drug price negotiation reduces future revenue

“The IRA, among other things, (i) directs the U.S. Department of Health and Human Services (HHS) to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare...” · word for word

Clinical development risk; early-stage data may not predict eventual approval or commercial success.

“Phase 1 dose-escalation; no efficacy or safety numbers provided in excerpt.”